| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Not applicable; this is a linker molecule used for bioconjugation.
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
This compound is a chemical linker used in the synthesis of ADCs. It does not have intrinsic biological activity but is used to conjugate antibodies to cytotoxic drugs. The Ala-Ala-Asn peptide sequence is designed for enzymatic cleavage, enabling targeted drug release. |
| ln Vivo |
This compound is used as a building block in the synthesis of therapeutic conjugates. Its in vivo activity is dependent on the final ADC construct.
|
| Enzyme Assay |
Fmoc-PEG4-Ala-Ala-Asn-PAB is a linker molecule. Its suitability for bioconjugation is assessed by standard chemical analytical methods, such as NMR and HPLC, to confirm purity and structure. The Fmoc group protects the N-terminus, and the PAB group provides a self-immolative spacer for drug release.
|
| Cell Assay |
Not applicable; this is a chemical linker used in synthesis, not a drug with direct cellular activity. Its use in cellular assays is as a component of ADCs.
|
| Animal Protocol |
This compound is not a drug itself but a synthetic intermediate. Its use in vivo is as a component of an ADC, where its properties contribute to the overall pharmacokinetics and pharmacodynamics of the conjugate.
|
| ADME/Pharmacokinetics |
Fmoc-PEG4-Ala-Ala-Asn-PAB has a molecular formula of C43H56N6O12 and a molecular weight of 848.94 g/mol. It is a cleavable 4-unit PEG peptide linker.
|
| Toxicity/Toxicokinetics |
This compound is a research chemical and should be handled with standard laboratory safety precautions. It is not for human use.
|
| References |
[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
|
| Additional Infomation |
Fmoc-PEG4-Ala-Ala-Asn-PAB is a specialized linker for ADC development. The Ala-Ala-Asn sequence is a substrate for specific proteases, enabling targeted drug release in tumor cells. The PEG spacer improves solubility and pharmacokinetic properties.
|
| Molecular Formula |
C43H56N6O12
|
|---|---|
| Molecular Weight |
848.93775177002
|
| Exact Mass |
848.395
|
| CAS # |
2055048-57-0
|
| PubChem CID |
123132085
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.1
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
61
|
| Complexity |
1360
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)N)C(=O)NC1=CC=C(C=C1)CO)NC(=O)CCOCCOCCOCCOCCNC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
|
| InChi Key |
SAXNVMPCIWDUGW-PBCNQIPESA-N
|
| InChi Code |
InChI=1S/C43H56N6O12/c1-28(40(53)47-29(2)41(54)49-37(25-38(44)51)42(55)48-31-13-11-30(26-50)12-14-31)46-39(52)15-17-57-19-21-59-23-24-60-22-20-58-18-16-45-43(56)61-27-36-34-9-5-3-7-32(34)33-8-4-6-10-35(33)36/h3-14,28-29,36-37,50H,15-27H2,1-2H3,(H2,44,51)(H,45,56)(H,46,52)(H,47,53)(H,48,55)(H,49,54)/t28-,29-,37-/m0/s1
|
| Chemical Name |
9H-fluoren-9-ylmethyl N-[2-[2-[2-[2-[3-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[4-(hydroxymethyl)anilino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1779 mL | 5.8897 mL | 11.7794 mL | |
| 5 mM | 0.2356 mL | 1.1779 mL | 2.3559 mL | |
| 10 mM | 0.1178 mL | 0.5890 mL | 1.1779 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
